Trial Profile
A retrospective, observational, real-world, safety and performance evaluation of BioMime Morph Sirolimus Eluting Coronary Stent System for coronary artery lesions - BioMime Morph
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors Meril Life Sciences
- 14 Jan 2019 Planned number of patients changed from 64 to 400.
- 25 Jun 2018 New trial record